Result Hip begins recruitment
The impact of REStrictive versUs LIberaL Transfusion strategy on cardiac injury and death in patients undergoing surgery for Hip Fracture (RESULT-Hip)
The RESULT-Hip trial is a multicentre, parallel group, randomised controlled, clinical and cost effectiveness trial with internal pilot funded by the NIHR Health Technology Assessment programme (NIHR-HTA 130875). IRAS project ID 299977 (Scotland). The co - Chief Investigators are Professor Mike Gillies and Professor Tim Walsh.
Hip fracture is the most common serious injury in older people. More than 95% go on to have surgery. This surgery is often high-risk as patients with hip fracture may already be frail and have other health problems including heart disease and anaemia. Research suggests that 30-40% of these patients have a blood transfusion around the time of operation, but there is uncertainty about what the trigger value for transfusion should be. The study will compare blood transfusion at two different levels of anaemia in people undergoing surgery for hip fracture.
People (≥60 years old), with hip fracture that become anaemic will be allocated to be transfused at one of two different blood count levels. Either a ‘restrictive’ level’ in line with current NICE guidelines (threshold Hb £75 g.L-1 , target of 75-90 g.L-1) or a higher “liberal” level (threshold Hb £90g/L , aim 90-110 g/L) for duration of inpatient admission or 30 days whichever is soonest. The primary outcome is death or major adverse cardiac events (MACE) within 30 days of surgery. Secondary outcomes will be measured at 30 and 120 days and include, all-cause mortality, MINS post-randomisation, individual MACE components, complications, hospital length of stay, HRQoL, resource use.
We will recruit 1964 participants from 30 sites across the UK. We are currently actively looking for sites. For more information, or to express an interest, please contact RESULTHip.Trial@ed.ac.uk